CN112645964B - Tyrosol-biotin small-molecule probe and preparation method and application thereof - Google Patents
Tyrosol-biotin small-molecule probe and preparation method and application thereof Download PDFInfo
- Publication number
- CN112645964B CN112645964B CN202011544003.3A CN202011544003A CN112645964B CN 112645964 B CN112645964 B CN 112645964B CN 202011544003 A CN202011544003 A CN 202011544003A CN 112645964 B CN112645964 B CN 112645964B
- Authority
- CN
- China
- Prior art keywords
- tyrosol
- formula
- reacting
- compound shown
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 229960002685 biotin Drugs 0.000 title claims abstract description 18
- 239000011616 biotin Substances 0.000 title claims abstract description 18
- 239000000523 sample Substances 0.000 title claims description 10
- 239000003068 molecular probe Substances 0.000 claims abstract description 17
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 7
- XIOUDVJTOYVRTB-UHFFFAOYSA-N 1-(1-adamantyl)-3-aminothiourea Chemical group C1C(C2)CC3CC2CC1(NC(=S)NN)C3 XIOUDVJTOYVRTB-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 238000005984 hydrogenation reaction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 235000011181 potassium carbonates Nutrition 0.000 claims description 4
- UFDULEKOJAEIRI-UHFFFAOYSA-N (2-acetyloxy-3-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I)=C1OC(C)=O UFDULEKOJAEIRI-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- OQWAXRPJEPTTSZ-UHFFFAOYSA-N [(2,3,4,5,6-pentafluorophenyl)-(2,2,2-trifluoroacetyl)oxy-$l^{3}-iodanyl] 2,2,2-trifluoroacetate Chemical compound FC1=C(F)C(F)=C(I(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F)C(F)=C1F OQWAXRPJEPTTSZ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- SZQUEWJRBJDHSM-UHFFFAOYSA-N iron(3+);trinitrate;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O SZQUEWJRBJDHSM-UHFFFAOYSA-N 0.000 claims description 3
- MAQAGRJURDEYDQ-UHFFFAOYSA-N 6-methylpyridine Chemical compound CC1=C=CC=C[N]1 MAQAGRJURDEYDQ-UHFFFAOYSA-N 0.000 claims description 2
- 101000878595 Arabidopsis thaliana Squalene synthase 1 Proteins 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims 2
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 claims 1
- OHZYBVJLACKLBS-UHFFFAOYSA-N C1=CC=CC=C1.FC(C(=O)OIOC(C(F)(F)F)=O)(F)F Chemical compound C1=CC=CC=C1.FC(C(=O)OIOC(C(F)(F)F)=O)(F)F OHZYBVJLACKLBS-UHFFFAOYSA-N 0.000 claims 1
- CAWUTUCTVSRAPN-UHFFFAOYSA-N IC1=CC=CC=C1.C(C)(C)(C)C(=O)[O].C(C)(C)(C)C(=O)[O] Chemical group IC1=CC=CC=C1.C(C)(C)(C)C(=O)[O].C(C)(C)(C)C(=O)[O] CAWUTUCTVSRAPN-UHFFFAOYSA-N 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 abstract description 47
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 abstract description 25
- 235000004330 tyrosol Nutrition 0.000 abstract description 25
- 230000008065 myocardial cell damage Effects 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 10
- 230000007954 hypoxia Effects 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 239000003480 eluent Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- -1 tyrosol small molecule Chemical class 0.000 description 3
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DZKPLZUSZXYHFB-UHFFFAOYSA-N [2,2-dimethylpropanoyloxy(phenyl)-$l^{3}-iodanyl] 2,2-dimethylpropanoate Chemical group CC(C)(C)C(=O)OI(OC(=O)C(C)(C)C)C1=CC=CC=C1 DZKPLZUSZXYHFB-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The invention discloses a tyrosol-biotin small molecular probe and a preparation method and application thereof. The tyrosol small molecular probe designed by the invention is subjected to in vitro activity test, and the result shows that the tyrosol small molecular probe has good activity on the protection of primary myocardial cell injury induced by hypoxia reoxygenation, can be used as a small molecular probe for researching the action mechanism of tyrosol, and has good application prospect in the medical field.
Description
Technical Field
The invention belongs to the technical field of medicinal chemistry, and particularly relates to a tyrosol-biotin small molecular probe and a preparation method and application thereof.
Background
Tyrosol (Tyrosol) is aglycone of salidroside, is one of main active ingredients in rhodiola plants, is one of main phenolic compounds in olive oil, and has strong antioxidant activity. Tyrosol has good pharmacological activity in preventing and treating nervous system diseases, protecting heart, liver and kidney, inhibiting inflammation, inhibiting oxidative stress, resisting thrombi, resisting atherosclerosis, resisting pathogenic microorganism, resisting tumor, etc. Oxidative stress is one of the important mechanisms of ischemia-reperfusion-induced myocardial injury, which leads to excessive accumulation of ROS and can trigger myocardial cell death, leading to heart failure. Research shows that tyrosol can activate SIRT1/AMPK/eNOS signal path, inhibit oxidative stress reaction and reduce myocardial ischemia-reperfusion injury of diabetic rat effectively. In addition, tyrosol can also promote Hsp70 expression, reduce caspase-8 level, inhibit ischemia reperfusion induced apoptosis and relieve myocardial cell injury by inhibiting ROS accumulation and activation of ERK and JNK.
In conclusion, although tyrosol has good antioxidant activity and effect of relieving myocardial cell injury in vitro, the structure-activity relationship research is less, the design and synthesis of active compounds are difficult points of research center, and the action target and action mechanism are not clear. Therefore, the design and synthesis of small molecular probes with biological activity are needed, and the method has important significance for researching the action target of tyrosol and the action mechanism for treating myocardial cell injury. As a common labeling group, biotin-tyrosol small molecular probes formed by biotin-tyrosol connection are not reported at present, so that an experimental report of an action target of biotin-tyrosol is obtained.
Disclosure of Invention
Aiming at the prior art, the invention provides a tyrosol-biotin small molecular probe and a preparation method and application thereof, aiming at overcoming the defects of the existing tyrosol action target and the research on the myocardial cell injury protection action mechanism.
In order to achieve the purpose, the invention adopts the technical scheme that: provides a tyrosol-biotin small molecular probe, the structure of the small molecular probe is shown as formula I,
wherein n is an integer of 1 to 5.
The tyrosol small molecule probe is preferably the following compound:
the preparation route of the tyrosol-biotin small molecule probe is as follows:
the preparation method comprises the following steps:
s1: mixing a compound shown as a formula II, a compound shown as a formula III and a base according to the proportion of 1: 2-5: 1-3, uniformly stirring, reacting for 10-20 h at 30-100 ℃, extracting, and concentrating to obtain an intermediate IV;
s2: and mixing the intermediate IV, the compound shown in the formula V and a base according to the proportion of 1: 0.6-1: 1-3, stirring uniformly, reacting for 10-20 h at 30-100 ℃, extracting, concentrating and purifying to obtain the product;
the preparation method can be further improved on the basis of the technical scheme as follows.
Further, the compound of formula II, the compound of formula III and the base are as follows 1: 3: 2 are co-dissolved in an organic solvent a.
Further, the intermediate IV, the compound of formula V and the base are as follows: 0.8: 2 in an organic solvent B.
Further, the base is at least one of triethylamine, diisopropylethylamine, pyridine, 2, 6-methylpyridine, piperidine, 1, 8-diazabicycloundecen-7-ene, 1, 4-diazabicyclo [2.2.2] octane, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide and calcium hydroxide.
Further, the organic solvent A is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide, dioxane and acetone. The dosage of the organic solvent A is 5-15 mL/g, preferably 10-12 mL/g, calculated by the compound shown in the formula II.
Further, the organic solvent B is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide, dioxane, acetone, dichloromethane, 1, 2-dichloroethane and chloroform. The amount of the organic solvent B is 5-15 mL/g, preferably 7-9 mL/g, based on the compound shown in the formula II.
Further, the preparation route of the compound represented by the formula V is as follows:
the preparation method comprises the following steps:
SS 1: reacting a compound of formula VI, an iodine reagent, and a nitrate salt in the ratio of 1: 0.1-0.5: 0.1-1 mass ratio, stirring uniformly, reacting at room temperature for 5-10 h, extracting, and concentrating to obtain a compound shown in a formula VII;
SS 2: dissolving a compound shown as a formula VII in an organic solvent D, and then adding a hydrogenation catalyst, wherein the mass ratio of the hydrogenation catalyst to the compound shown as the formula VII is 1-4: 20; and introducing hydrogen into the reaction device at the temperature of 20-60 ℃, reacting for 4-10 hours, and then filtering and concentrating to obtain the catalyst.
Further, the iodine reagent is bis (tert-butylcarbonyloxy) iodobenzene, [ bis (trifluoroacetyloxy) iodo ] benzene, [ bis (trifluoroacetyloxy) iodo ] pentafluorobenzene or diacetoxyiodobenzene; the nitrate is zinc nitrate hexahydrate, ferric nitrate nonahydrate or cupric nitrate trihydrate.
Further, the organic solvent C is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1, 2-dichloroethane, chloroform, dimethyl sulfoxide, methanol, ethanol, acetonitrile and trifluoroethanol, and the dosage of the organic solvent C is 10-20 mL/g, preferably 12-15 mL/g based on the compound shown in the formula VI; the organic solvent D is at least one of methanol, ethanol, isopropanol, ethyl acetate, propyl acetate, butyl acetate, tetrahydrofuran and 2-methyltetrahydrofuran, and the dosage of the organic solvent D is 30-60 mL/g, preferably 40-50 mL/g based on the compound shown in the formula VII.
Further, the hydrogenation catalyst is Raney nickel or Pd/C with the mass fraction of 5%.
The tyrosol-biotin small molecular probe prepared by the invention has good prevention and treatment effects on primary myocardial cell injury induced by hypoxia reoxygenation, and can be used for preparing corresponding treatment medicines.
The invention has the beneficial effects that:
1. a novel tyrosol small molecular probe which takes alkane as a connecting chain and biotin as a report group is synthesized.
2. The tyrosol small molecular probe has good water solubility and a protective effect on myocardial cell injury, provides a basis and a template molecule for 'fishing' a target spot and researching an action mechanism of tyrosol, and has important academic research value and application prospect.
3. The synthetic method has the advantages of short route, simple and convenient operation, mild reaction conditions and high selectivity, and provides a better method for designing the molecular probe of a complex natural product.
Drawings
FIG. 1 is a nuclear magnetic hydrogen spectrum of Compound I obtained in example 14;
FIG. 2 is a nuclear magnetic carbon spectrum of Compound I obtained in example 14;
FIG. 3 is a graph of the protective effect of small molecule probes on hypoxia-reoxygenation-induced primary cardiomyocyte injury.
Detailed Description
The following examples are provided to illustrate specific embodiments of the present invention.
Example 1: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 934mg diacetoxyiodobenzene acetate, 1.3g zinc nitrate hexahydrate, and 25mL acetonitrile were added, followed by 2.0g 2-aminobutyric alcohol (VI). The reaction solution was reacted at room temperature overnight, the TLC detection of the starting material was essentially complete, water was added, extraction was carried out with ethyl acetate and the organic phase was concentrated to give a tan solid 1.67g with a yield of 63%.
Example 2: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 1.47g of bis (tert-butylcarbonyloxy) iodobenzene, 1.3g of zinc nitrate hexahydrate and 25mL of acetonitrile were charged, and 2.0g of tyrosol was added. The reaction solution was reacted at room temperature overnight, the TLC detection of the starting material was essentially complete, water was added, extraction was carried out with ethyl acetate and the organic phase was concentrated to give 1.59g of a tan solid with a yield of 60%.
Example 3: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 1.25g of [ bis (trifluoroacetoxy) iodo ] benzene, 1.3g of zinc nitrate hexahydrate and 25mL of acetonitrile were charged, and 2.0g of tyrosol was added. The reaction solution is reacted at room temperature overnight, the TLC detection shows that the raw materials are basically completely reacted, water is added, ethyl acetate is used for extraction, and the organic phase is concentrated to obtain 2.12g of brown yellow solid with the yield of 80%.
Example 4: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 1.51g of [ bis (trifluoroacetoxy) iodo ] pentafluorobenzene, 1.3g of zinc nitrate hexahydrate and 25mL of acetonitrile were added, and 2.0g of tyrosol was added. The reaction solution was reacted at room temperature overnight, the TLC detection of the starting material was essentially complete, water was added, extraction was carried out with ethyl acetate and the organic phase was concentrated to give 2.01g of a tan solid with a yield of 76%.
Example 5: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 1.87g of [ bis (trifluoroacetoxy) iodo ] benzene, 2.63g of ferric nitrate nonahydrate and 40mL of acetonitrile were added, and 3.0g of tyrosol was added. The reaction solution was reacted at room temperature overnight, the TLC detection of the starting material was essentially complete, water was added, extraction was carried out with ethyl acetate and the organic phase was concentrated to give a tan solid 3.38g with a yield of 85%.
Example 6: preparation of 2-nitrotyrosol (VII)
In a 50mL round bottom flask, 1.56g of [ bis (trifluoroacetoxy) iodo ] benzene, 1.23g of copper nitrate trihydrate and 30mL of acetonitrile were added, 2.0g of tyrosol was added. The reaction solution was reacted at room temperature overnight, the TLC detection of the starting material was essentially complete, water was added, extraction was carried out with ethyl acetate and the organic phase was concentrated to give a tan solid 1.99g with a yield of 75%.
Example 7: preparation of 2-aminobutyric alcohol (V)
Dissolving 2-nitrotyrosol (4g) in 95% ethanol, adding 400mg of 5 wt% Pd-C (containing 50% of water), hydrogenating at 40 ℃ under normal pressure, reacting for 6h, completely reacting the raw materials, performing suction filtration, and concentrating the filtrate to obtain dark green solid 2-aminobutyric alcohol (3.21 g), wherein the yield is 96%.
Example 8: preparation of 2-aminobutyric alcohol (V)
Dissolving 2-nitrotyrosol (2g) in tetrahydrofuran, adding 250mg of 5 wt% Pd-C (containing 50% of water), hydrogenating at 50 ℃ under normal pressure, reacting for 8h, completely reacting the raw materials, performing suction filtration, and concentrating the filtrate to obtain dark green solid 2-aminobutyric alcohol (1.57 g), wherein the yield is 94%.
Example 9: preparation of 2-aminobutyric alcohol (V)
Dissolving 2-nitrotyrosol (3g) in methanol, adding 320mg of 5 wt% Pd-C (containing 50% of water), hydrogenating at 30 ℃ under normal pressure, reacting for 6h, completely reacting the raw materials, performing suction filtration, and concentrating the filtrate to obtain 2.48g of dark green solid 2-aminobutyric alcohol, wherein the yield is 99%.
Example 10: preparation of Compound (IV)
976mg of biotin represented by the formula II, 2.6g of 1, 4-dibromobutane and 1.1g of potassium carbonate were put into 10mL of N, N-dimethylformamide, and the reaction was stirred at 60 ℃ for 10 hours. After the reaction is finished, adding water, extracting by dichloromethane, concentrating an organic phase to obtain a jelly, and performing silica gel column chromatography, wherein dichloromethane and methanol are mixed according to a volume ratio of 15: 1 as eluent, and evaporating the eluent to obtain 1.07g of light yellow solid with a yield of 70%.
Example 11: preparation of Compound (IV)
732mg of biotin represented by the formula II, 1.95g of 1, 4-dibromobutane and 912mg of 1, 8-diazabicycloundecen-7-ene (DBU) were put into 8mL of N, N-dimethylformamide and reacted with stirring at 55 ℃ for 16 hours. After the reaction is finished, adding water, extracting by dichloromethane, concentrating an organic phase to obtain a jelly, and performing silica gel column chromatography, wherein dichloromethane and methanol are mixed according to a volume ratio of 15: 1 as eluent, and evaporating the eluent to obtain 624mg of light yellow solid with a yield of 55%.
Example 12: preparation of Compound (I)
Dissolving 280mg of a compound shown as a formula IV in N, N dimethylformamide (2mL), adding 110mg of 2-aminobutyric alcohol and 100mg of sodium bicarbonate, and reacting the reaction solution at 55 ℃ for 16h after uniformly stirring; after the reaction is finished, performing silica gel column chromatography, wherein dichloromethane and methanol are mixed according to the volume ratio of 10: 1 as eluent, and evaporating the solvent from the eluent to obtain 257mg of yellow viscous oil with a yield of 77%.
Example 13: preparation of Compound (I)
Dissolving 300mg of a compound shown as a formula IV in N, N dimethylformamide (3mL), adding 98mg of 2-amino tyrosol and 221mg of potassium carbonate, uniformly stirring, and reacting the reaction solution at 55 ℃ for 20 h; after the reaction is finished, performing silica gel column chromatography, wherein dichloromethane and methanol are mixed according to the volume ratio of 10: 1 as eluent, and evaporating the solvent from the eluent to obtain 293mg of yellow viscous oil with the yield of 81%.
Example 14: preparation of Compound (I)
Dissolving 200mg of a compound shown as a formula IV in N, N dimethylformamide (2mL), adding 66mg of 2-amino tyrosol and 161mg of 1, 8-diazabicycloundecen-7-ene (DBU), uniformly stirring, and reacting the reaction solution at 55 ℃ for 10 hours; after the reaction is finished, performing silica gel column chromatography, wherein dichloromethane and methanol are mixed according to the volume ratio of 10: 1 as eluent, and evaporating the solvent from the eluent to obtain 157mg of yellow viscous oil with a yield of 66%.
The spectral data of the prepared compound I were resolved as follows:
1H NMR(CD3OD,500MHz)δ1.42-1.47(m,2H),1.56-1.78(m,8H),2.36(t,J=7.35Hz,2H),2.68-2.72(m,3H),2.87-2.89(m,1H),3.16-3.18(m,3H),3.71(t,J=7.25Hz,2H),4.14(t,J=6.0Hz,2H),4.26-4.28(m,1H),4.44-4.47(m,1H),6.42(dd,J=1.95,7.9Hz,1H),6.53(d,J=1.9Hz,1H),6.62(d,J=7.85Hz,1H)ppm.
13C NMR(CD3OD,125MHz)δ24.64,25.58,26.00,28.08,28.35,33.53,38.77,39.67,43.48,55.59,60.22,61.99,63.45,64.01,112.12,113.27,117.45,130.40,136.74,143.10,164.71,174.14ppm.
HRMS-ESI:calculated for C22H34N3O5S[M+H]+:452.2214,found:452.2227.
experimental example pharmacodynamic experiment of Salidroside-biotin small molecule probe
Protection activity test for hypoxia reoxygenation-induced primary myocardial cell injury
1. Drugs and reagents: test samples, DMEM, 10% Fetal Bovine Serum (FBS), dimethyl sulfoxide (DMSO), Lactate Dehydrogenase (LDH) cytotoxicity detection kit.
2. The instrument comprises the following steps: clean bench, CO2Incubator, multifunctional inverted microscope, centrifuge, and 96-well culture plate with automatic microplate reader.
3. Cell lines: primary suckling mouse cardiac muscle cells.
4. Preparing a sample: the tyrosol small molecular probe prepared by the invention is taken, a compound is dissolved by DMSO, ultrasonic dissolution is carried out, the concentration is 200mM, and the obtained medicine solution is stored at the temperature of minus 20 ℃.
5. The specific experimental method comprises the following steps: inoculating primary suckling mouse myocardial cells into a 96-well plate, culturing for 24H, and setting a control group, an anoxic reoxygenation model group (H/R) and an H/R + tyrosol-biotin group. Respectively pre-protecting cells with tyrosol-biotin micromolecules with different concentrations (50 and 100 mu mol/L), and culturing in a cell culture box for 12 h; then, the cells are subjected to hypoxia for 4 hours and reoxygenation for 2 hours to form a myocardial cell hypoxia reoxygenation injury model, the LDH release rate of each hole of cells is detected by using a Lactate Dehydrogenase (LDH) cytotoxicity detection kit, so that the protective effect of tyrosol-biotin small molecules on primary myocardial cell injury induced by hypoxia reoxygenation is observed, and the experimental result is shown in figure 3.
6. The experimental results are as follows: the tyrosol small molecular probe disclosed by the invention has better activity on protecting primary myocardial cell injury induced by hypoxia reoxygenation, has an application prospect of treating myocardial cell injury, and can be applied to research on tyrosol 'fishing' targets and action mechanisms thereof.
While the present invention has been described in detail with reference to the embodiments, it should not be construed as limited to the scope of the patent. Various modifications and changes may be made by those skilled in the art without inventive step within the scope of the appended claims.
Claims (10)
2. The method for preparing tyrosol-biotin small molecule probes according to claim 1, comprising the steps of:
s1: mixing a compound shown as a formula II, a compound shown as a formula III and a base according to the proportion of 1: 2-5: 1-3, uniformly stirring, reacting for 10-20 h at 30-100 ℃, extracting, and concentrating to obtain an intermediate IV;
s2: and mixing the intermediate IV, the compound shown in the formula V and a base according to the proportion of 1: 0.6-1: 1-3, stirring uniformly, reacting for 10-20 h at 30-100 ℃, extracting, concentrating and purifying to obtain the product;
3. the method of claim 2, wherein: the alkali is at least one of triethylamine, diisopropylethylamine, pyridine, 2, 6-methylpyridine, piperidine, 1, 8-diazabicycloundeca-7-ene, 1, 4-diazabicyclo [2.2.2] octane, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide and calcium hydroxide.
4. The method of claim 2, wherein: the organic solvent A is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dimethyl sulfoxide, N dimethylformamide, N-dimethylacetamide, dioxane and acetone.
5. The method of claim 2, wherein: the organic solvent B is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dimethyl sulfoxide, N dimethylformamide, N-dimethylacetamide, dioxane, acetone, dichloromethane, 1, 2-dichloroethane and chloroform.
6. The method according to claim 2, wherein the compound of formula V is prepared by the following steps:
SS 1: reacting a compound of formula VI, an iodine reagent, and a nitrate salt in the ratio of 1: 0.1-0.5: 0.1-1 mass ratio, stirring uniformly, reacting at room temperature for 5-10 h, extracting, and concentrating to obtain a compound shown in a formula VII;
SS 2: dissolving a compound shown as a formula VII in an organic solvent D, and then adding a hydrogenation catalyst, wherein the mass ratio of the hydrogenation catalyst to the compound shown as the formula VII is 1-4: 20; and introducing hydrogen into the reaction device at the temperature of 20-60 ℃, reacting for 4-10 hours, and then filtering and concentrating to obtain the catalyst.
7. The method of claim 6, wherein: the iodine reagent is bis (tert-butyl carbonyl oxygen) iodobenzene, [ bis (trifluoroacetoxy) iodine ] benzene, [ bis (trifluoroacetoxy) iodo ] pentafluorobenzene or diacetoxy iodobenzene; the nitrate is zinc nitrate hexahydrate, ferric nitrate nonahydrate or copper nitrate trihydrate.
8. The method of claim 6, wherein: the organic solvent C is one or two of tetrahydrofuran, 2-methyltetrahydrofuran, dichloromethane, 1, 2-dichloroethane, chloroform, dimethyl sulfoxide, methanol, ethanol, acetonitrile and trifluoroethanol; the organic solvent D is at least one of methanol, ethanol, isopropanol, ethyl acetate, propyl acetate, butyl acetate, tetrahydrofuran and 2-methyltetrahydrofuran.
9. The method of claim 6, wherein: the hydrogenation catalyst is Raney nickel or Pd/C with the mass fraction of 5%.
10. The use of the tyrosol-biotin small molecule probe of claim 1 in the preparation of a medicament for the prevention and treatment of primary cardiomyocyte injury induced by hypoxia-reoxygenation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011544003.3A CN112645964B (en) | 2020-12-24 | 2020-12-24 | Tyrosol-biotin small-molecule probe and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011544003.3A CN112645964B (en) | 2020-12-24 | 2020-12-24 | Tyrosol-biotin small-molecule probe and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112645964A CN112645964A (en) | 2021-04-13 |
CN112645964B true CN112645964B (en) | 2021-10-15 |
Family
ID=75360120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011544003.3A Active CN112645964B (en) | 2020-12-24 | 2020-12-24 | Tyrosol-biotin small-molecule probe and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112645964B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476951A (en) * | 2011-02-16 | 2013-12-25 | 海德威技术公司 | Methods and compositions for the target-localized anchoring of detectable label |
-
2020
- 2020-12-24 CN CN202011544003.3A patent/CN112645964B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103476951A (en) * | 2011-02-16 | 2013-12-25 | 海德威技术公司 | Methods and compositions for the target-localized anchoring of detectable label |
Non-Patent Citations (1)
Title |
---|
Catechol Type Polyphenol Is a Potential Modifier of Protein Sulfhydryls: Development and Application of a New Probe for Understanding the Dietary Polyphenol Actions;Takeshi Ishii,等;《Chem. Res. Toxicol.》;20091009;第22卷;第1689-1698页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112645964A (en) | 2021-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220024843A1 (en) | Methods of synthesizing cannabigergol, cannabigerolic acid, and analogs thereof | |
US5192817A (en) | Phenanthrene derivatives | |
EP1860103A1 (en) | Anticancer compound, intermediate therefor, and processes for producing these | |
CZ297988A3 (en) | Beta-d-phenylthioxyloside derivative, process of its preparation and a therapeutic composition in which said derivative is comprised | |
WO2007009590A1 (en) | Process for the preparation of phenolic compounds | |
DE69127691T2 (en) | BE-13793C DERIVATIVE WITH ANTITUARY EFFECT | |
CN112645964B (en) | Tyrosol-biotin small-molecule probe and preparation method and application thereof | |
SU1054352A1 (en) | N-glycosyl derivatives of daunorubicine having antibiotic effect | |
NO750294L (en) | ||
CN112552358B (en) | Salidroside-biotin small molecular probe and preparation method and application thereof | |
Kawai et al. | Crystal Structures of 5 α, 6 α-Epoxy and 2, 3-Dihydro Derivatives of Physalin B, a 13, 14-Seco-16, 24-cyclosteroid, and Their 1H NMR Spectral Analysis | |
PL100426B1 (en) | METHOD OF MAKING APVINKAMINOL ESTRAS | |
US7368593B1 (en) | Method of selective esterification | |
CN107955057B (en) | Fusidic acid chemical modifier and preparation method and application thereof | |
CN105175352A (en) | Preparation method of nitazoxanide | |
EP0044954B1 (en) | Anthracyclinglycosides, their preparation and pharmaceutical preparations | |
US5326786A (en) | 5,6,7,9-tetrahydro-1,2,3-trimethoxy-9-oxobenzo[alpha]heptalene derivative and pharmaceutical use | |
CN115433200B (en) | Tetracyclic compound containing chroman-4-one structure, synthesis method and application | |
US5504221A (en) | Method for resolving racemic compounds | |
US2944078A (en) | Derivatives of dibenzo cycloheptadiene and a process of preparing same | |
CN117164462B (en) | Diaryl methane compound and preparation method and application thereof | |
JPS6335578A (en) | Benzoxazino or benzothiazinorifamycin derivative | |
CN107325149B (en) | A kind of radix glycyrrhizae gadoleic acid derivative and preparation method thereof and purposes | |
RU2316557C1 (en) | 6,6-dimethyl-8-oxo-5,6,8,9-tetrahydrobenzo[f]-pyrrolo[2,1-alpha]isoquinoline-9-spiro-2-(3-aroyl-4-hydroxy-1-o-hydroxyphenyl-5-oxo-2,5-dihydro-1h-pyrroles) and 6,6-dimethyl-8-oxo-5,6,8,9-tetrahydrobenzo[f]pyrrolo[2,1-alpha]isoquinoline-9-spiro-2-(3-benzoyl-4-hydroxy-1-o-hydroxyphenyl-5-oxo-2,5-dihydrio-1h-pyrrole) eliciting analgesic activity and method for their preparing | |
CN108602758A (en) | The method for preparing trans-4-amino -1- cyclohexyls carboxylic acid and its derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |